Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Corbus Pharmaceuticals appointed Nishant Saxena, former Managing Director at Evercore, as its first Chief Business Officer to support the company's transition to registrational-stage development. The company scheduled a conference call for May 26 to discuss updated Phase 1/2 data for its lead oncology asset CRB-701, which will be presented at the ASCO Annual Meeting in late May.
Key figures
- Drug Name
- CRB-701
- Phase Of Trial
- Phase 1/2
- Crb913 study size
- 240
- Crb913 study duration
- 16-week
- Crb701 hnscc participants
- 75
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.